뉴스

Kalam School Of Ideology: Why Annamalai Chose The Scientist As His Guiding Light

K Annamalai quits BJP, launches 'We The Leader' movement promoting Kalam-inspired ethics and nationalism.

AHER and TJU collaboration has fostered world-class research, says U.S. scientist

Chennai-based CIBA scientists develop soil-friendly fertilisers from fish waste

The products address the twin challenges of scientific fish waste disposal and the growing need for eco-friendly nutrient sources that enhance soil fertility and agricultural productivity

Below-normal monsoon for Andhra Pradesh, but short, heavy spells likely: IMD

The State is likely to see more thunderstorms, lightning and strong winds during the southwest monsoon, affecting the agricultural activities, says IMD senior scientist

KAHER to award honorary doctorate to U.S. scientist during convocation

As many as 1,810 degrees, certificates to be awarded on Friday

What's Delaying Monsoon? Scientists Point To Indian Ocean, El Nino

Centre has put itself on alert mode to deal with the possible impact of El Nino (Representational)

Melissa Casias' body discovered: From Los Alamos to NASA, the timeline behind America's missing scientists mystery

Melissa Casias, a nuclear lab worker, was found dead in Carson National Forest after disappearing on 26 June, 2025. Her case adds to a trend of mysterious deaths and disappearances among individuals connected to US nuclear and aerospace programs. Here we examine the timeline of these events.

Climate Change Will Make Super El Nino Especially Severe, Scientists Warn

WMO forecasts suggest a strong El Nino is possible.

Strong El Niño likely this year, climate change could intensify extreme weather: WMO

The World Meteorological Organization warns of an 80% chance of a strong El Niño developing this year, potentially amplifying extreme weather events due to climate change. This phenomenon, characterized by warmer Pacific waters, could lead to intensified heatwaves, droughts, and floods globally. Scientists fear this combination may make 2027 the hottest year on record.

Europe AI startup co-founder warns region cannot afford to rely on US for Superintelligence

Europe faces a critical need to develop its own superintelligence. Mistral AI's chief scientist warns against relying on American tech giants for future AI advancements. This push for independence is driven by geopolitical shifts. Mistral AI aims to provide European-hosted AI models. However, funding remains a significant challenge for the startup.

'De-extincting' the Moa: The audacious bid to bring back the giant bird

A Texas-based firm, Colossal Biosciences, claims a breakthrough in de-extinction, developing an artificial eggshell system to potentially resurrect the extinct moa. While scientists express skepticism due to a lack of peer-reviewed data, the project is driven by ecological restoration, cultural significance for Māori, and the development of biotechnology for living endangered species.

Nagaland yields a new-to-science cascade frog species

Recorded from Kiphire district, the frog has been named Amolops kamal to honour the mentor of one of the six scientists involved in the study

Scientists develop 'smart paint' that reflects 97% of sunlight and could reduce AC use during heatwaves

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

CCMB scientists identify rare gene behind Indian girl’s red hair

From this, researchers have provided fresh insight into the country’s complex genetic landscape by uncovering the role of the MC1R gene (melanocortin 1 receptor), a key regulator of skin and hair pigmentation.

CCMB scientists identify rare gene behind Indian girl’s red hair

'I warned these guys': American scientist hits back at Oracle's Larry Ellison on AI's big problem

American scientist Gary Marcus has hit back at Oracle founder Larry Ellison's claim that AI models like ChatGPT, Gemini, Grok, and Llama are commoditised because they train on the same public data. Marcus says he warned of this exact "no moat" problem two years ago, predicting price wars and weak differentiation. He argues Silicon Valley's refusal to listen will cost the industry billions.

Quote of the Day: Alan Kay on AI— ‘Some people worry that artificial intelligence will make us feel inferior, but…'

Quote of the Day: As artificial intelligence continues to reshape industries and daily life, computer scientist Alan Kay offers a thought-provoking perspective on humanity's place in the age of machines.

Huawei takes on rivals with new chips push

Shanghai: China's electronics giant Huawei is using a new principle for its chip designing framework that focuses more on cutting transmission time than shrinking transistors. The company plans to use innovative technologies like LogicFolding based on this principle to continuously compress signal propagation delay and improve transistor density.The current chip design framework rests on Moore's law which dates back decades when Intel co-founder Gordon Moore posited in 1965 that the number of transistors on a microchip will double every two years.The Tau Scaling principle could be a revolutionary step in the future of chip designing as it shifts focus from geometric scaling to time scaling. The principle that governs modern advanced chips is to shrink the size of transistors to fit onto a microchip. But this mechanism may have a handicap. It may not be easy to shrink them beyond a point. This is where time scaling becomes useful as it makes cutting signal transmission time the underlying principle of future chip designs.Also Read: PLI 2.0: India bets big on making more of the smartphone at homeThe innovative core technologies like LogicFolding, which Huawei will use for its Kirin chips scheduled to launch in Fall 2026, will work on the Tau Scaling principle in order to drive up performance, energy efficiency, and transistor density."With the t Scaling Law, we look forward to working closely with scientists, engineers, and industry partners around the world to drive the sustainable development of the semiconductor and electronics industries," Huawei's semiconductor chief He Tingbo noted.Huawei's new chip design breakthrough will help the chip maker to sidestep the US sanctions that restrict access to advanced lithography machines from ASML.Also Read: Indian semicon firm Netrasemi plans mass production of its first chip this yearBy 2031, Huawei is aiming for high-end chips based on the t Scaling Law that are expected to feature a transistor density that is equivalent to 14 A (1.4 nm) processes."This is a breakthrough for Huawei, but it's not a threat for TSMC," Reuters quoted Nvidia CEO Jensen Huang, who was in Taipei on Thursday."TSMC has been using die stacking and 3D packaging for how long now? Almost 10 years. And so TSMC's technology is very advanced," he added.A Reuters report mentioned Bernstein analysts cautioning in a note that while stacking multiple chip layers boosts transistor density, there's risk of increasing power density and overheating chips.

ISRO Detects Possible Ice Beneath Moon's Surface Using Chandrayaan-2 Data

Scientists used advanced radar polarimetric methods to study the craters.